Wyeth Reports Earnings Results for the 2007 Fourth Quarter and... (rrent business model and working with ou...)

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

Date:1/31/2008

rrent business model and working with our management team to find approaches to help us operate more efficiently over the long-term, and continue as a driving force in global healthcare."

2007 Fourth Quarter and Full Year Product Highlights

Set forth below is a table of net revenue for Wyeth's principal products for the 2007 fourth quarter and full year together with the percentage changes from the comparable period in the prior year:

(UNAUDITED)

Three Months Ended Full Year Ended

12/31/2007 12/31/2007

Increase/ Increase/

($ in millions) (Decrease) ($ in millions) (Decrease)

Principal Products

Effexor $968 3% $3,794 2%

Prevnar 556 11% 2,439 24%

Enbrel (outside the

U.S. and Canada) 565 36% 2,045 36%

Protonix 461 10% 1,911 6%

Nutrition 393 28% 1,443 20%

Alliance Revenue (1) 321 (13)% 1,294 (3)%

Zosyn/Tazocin 292 17% 1,137 17%

Premarin Family 264 1% 1,055 0%

Centrum 204 13% 705 7%

Advil 186 8% 684 10%

(1) Alliance revenue reflects revenue to Wyeth derived from sales of

Enbrel (in the United States and Canada), Altace and the CYPHER stent.

Product Highlights

Enbrel(R) continued to post strong revenue growth during 2007. Enbrel sales in the United States and Canada, reported by Wyeth's marketing part
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and...(rrent business model and working with ou...)